STOCK TITAN

Amgen Inc - AMGN STOCK NEWS

Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.

Amgen Inc. (NASDAQ: AMGN) is a leading American multinational biopharmaceutical company, established in 1980 and headquartered in Thousand Oaks, California. As one of the largest independent biotechnology companies globally, Amgen specializes in discovering, developing, manufacturing, and delivering innovative human therapeutics. The company focuses on areas of high unmet medical need and leverages its expertise in advanced human genetics to develop solutions that dramatically improve people's lives.

Amgen's portfolio includes a range of flagship drugs such as red blood cell boosters Epogen and Aranesp, immune system enhancers Neupogen and Neulasta, and treatments for inflammatory diseases like Enbrel and Otezla. Additionally, the company has a strong presence in the oncology sector with products like Vectibix, Prolia, Evenity, and Kyprolis. Notably, the acquisition of Onyx Pharmaceuticals bolstered Amgen's oncology portfolio.

Recent launches include innovative therapies such as Repatha for cholesterol management, Aimovig for migraines, Lumakras for lung cancer, and Tezspire for asthma. In 2023, Amgen's acquisition of Horizon Therapeutics introduced several rare-disease drugs to its portfolio, including Tepezza for thyroid eye disease. Amgen also continues to expand its biosimilar portfolio, reinforcing its commitment to making advanced treatments more accessible.

Amgen's financial health is robust, with significant growth in revenues and product sales. The company's strategic partnerships and acquisitions have continually strengthened its market position. For instance, the recent Phase 3 SPROUT study demonstrated the efficacy and safety of Otezla in pediatric patients, highlighting Amgen's ongoing commitment to addressing various health needs. Furthermore, the company’s dedication to innovation is evident from its extensive pipeline of investigational drugs targeting various conditions.

Amgen has been acknowledged for its workplace culture and environmental initiatives, being named one of

Rhea-AI Summary
Amgen to present at Bank of America Merrill Lynch Global Healthcare Conference on Sept. 14, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
conferences
-
Rhea-AI Summary
Amgen announces positive data from Phase 1b study of LUMAKRAS in first-line treatment of KRAS G12C-mutated NSCLC, with a confirmed objective response rate of 65% and disease control rate of 100%. Phase 3 study initiated.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Amgen to present at Morgan Stanley Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.98%
Tags
conferences
Rhea-AI Summary
Amgen and Horizon Therapeutics resolve pending FTC lawsuit, clearing the way for Amgen's acquisition of Horizon
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
-
Rhea-AI Summary
Amgen and Horizon Therapeutics resolve pending FTC lawsuit, clearing path for acquisition
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
-
Rhea-AI Summary
Amgen to present at Wells Fargo Healthcare Conference and Citi Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
conferences
Rhea-AI Summary
Amgen announces positive results from Phase 2 OCEAN(a)-DOSE study of olpasiran, showing a lasting effect on Lp(a) reduction nearly a year after the last dose. No new safety concerns identified. Amgen convenes LDL Awareness to Action Implementation Consortium to improve LDL-C testing and evidence-based treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Amgen's LUMAKRAS® (sotorasib) is set for review by the FDA Oncologic Drugs Advisory Committee for full approval in treating KRAS G12C-mutated NSCLC. LUMAKRAS has shown positive results in multiple studies and is approved in various markets. The comprehensive data package will be discussed at the meeting on Oct. 5, 2023. A PDUFA target action date of Dec. 24, 2023, has been set.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.18%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.45%
Tags
Rhea-AI Summary
Amgen declares a $2.13 per share dividend for the third quarter of 2023, payable on September 8, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
dividends

FAQ

What is the current stock price of Amgen (AMGN)?

The current stock price of Amgen (AMGN) is $264.49 as of December 24, 2024.

What is the market cap of Amgen (AMGN)?

The market cap of Amgen (AMGN) is approximately 142.2B.

Amgen Inc

Nasdaq:AMGN

AMGN Rankings

AMGN Stock Data

142.17B
536.09M
0.21%
81.11%
1.82%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States of America
THOUSAND OAKS